These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 33534040)

  • 1. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
    Nikolic M; Zivkovic V; Jovic JJ; Sretenovic J; Davidovic G; Simovic S; Djokovic D; Muric N; Bolevich S; Jakovljevic V
    Heart Fail Rev; 2022 May; 27(3):935-949. PubMed ID: 33534040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 3. Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
    Yu H; Tang W; Greasley PJ; Penland RC; Boulton DW; Hallow KM
    J Clin Pharmacol; 2021 May; 61(5):636-648. PubMed ID: 33091173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis.
    Gronda E; Lopaschuk GD; Arduini A; Santoro A; Benincasa G; Palazzuoli A; Gabrielli D; Napoli C
    Can J Physiol Pharmacol; 2022 Feb; 100(2):93-106. PubMed ID: 35112597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient.
    Severino P; D'Amato A; Prosperi S; Costi B; Angotti D; Birtolo LI; Chimenti C; Lavalle C; Maestrini V; Mancone M; Fedele F
    Heart Fail Rev; 2023 May; 28(3):709-721. PubMed ID: 34654997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?
    Pabel S; Hamdani N; Luedde M; Sossalla S
    Curr Heart Fail Rep; 2021 Oct; 18(5):315-328. PubMed ID: 34523061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors.
    Al Thani NA; Hasan M; Yalcin HC
    J Cardiovasc Transl Res; 2023 Oct; 16(5):975-986. PubMed ID: 37052784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of SGLT-2 inhibitors in heart failure.
    Velliou M; Polyzogopoulou E; Ventoulis I; Parissis J
    Expert Rev Clin Pharmacol; 2023 Feb; 16(2):149-160. PubMed ID: 36701817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure.
    Karangelis D; Mazer CD; Stakos D; Tzifa A; Loggos S; Verma S; Mitropoulos F
    Curr Pharm Des; 2021; 27(8):1051-1060. PubMed ID: 33143620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME; Kosiborod M
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
    Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
    Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.
    Palmiero G; Cesaro A; Vetrano E; Pafundi PC; Galiero R; Caturano A; Moscarella E; Gragnano F; Salvatore T; Rinaldi L; Calabrò P; Sasso FC
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
    Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
    Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growing role of SGLT2i in heart failure: evidence from clinical trials.
    Varadhan A; Stephan K; Gupta R; Vyas AV; Ranchal P; Aronow WS; Hawwa N; Lanier GM
    Expert Rev Clin Pharmacol; 2022 Feb; 15(2):147-159. PubMed ID: 35264076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?
    Correale M; Petroni R; Coiro S; Antohi EL; Monitillo F; Leone M; Triggiani M; Ishihara S; Dungen HD; Sarwar CMS; Memo M; Sabbah HN; Metra M; Butler J; Nodari S
    Heart Fail Rev; 2022 Jul; 27(4):1147-1163. PubMed ID: 34097173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors.
    Chrysant SG; Chrysant GS
    Expert Rev Cardiovasc Ther; 2022 Mar; 20(3):223-232. PubMed ID: 35320057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland.
    Lymperopoulos A; Borges JI; Cora N; Sizova A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.